Kintor Pharma-B (09939) has unveiled its interim financial results for the period ending June 30, 2026, showcasing a notable surge in revenue from RMB 6 million in the prior-year period to RMB 52 million during the first half of the year. Concurrently, the company recorded a net loss of RMB 75.78 million, marking a reduction of 8.99% year-over-year, with a loss per share of RMB 0.15.

The company attributed the significant revenue growth primarily to the robust performance of its new premium cosmetics brand KOSHINÉ, driven by live-streaming e-commerce sales. This brand leverages KX-826, one of the company's core pharmaceutical assets, as its principal ingredient, fueling global sales momentum. Management indicated that the group is actively exploring diverse strategies to further accelerate the international commercialization of its cosmetic products.

Looking ahead, the company intends to utilize the cash flows generated from its cosmetics sales operations to fund the development and commercialization of its core drug candidates, including KX-826, GT20029, and other pipeline assets. Simultaneously, Kintor Pharma-B reaffirmed its commitment to adhering to its established business strategy for its listed operations.

The narrowing of the net loss is primarily attributable to a reduction in research and development expenses. This decrease was partially offset by an escalation in selling and marketing costs, which rose mainly due to heightened promotional activities and marketing expenditures.